{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-004927","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.098909+00:00","generated_at":"2026-05-16T02:59:08.375416+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Grace Therapeutics reports Q3 FY2026 net loss of $2.3M; cash $18.7M; FDA PDUFA date April 23, 2026 for GTx-104","bullets":["Net loss of $2.3M ($0.14 per share) improved from $4.2M loss ($0.36 per share) in prior year quarter.","FDA set April 23, 2026 as PDUFA target date for GTx-104 NDA for aSAH treatment.","Cash and equivalents $18.7M as of Dec 31, 2025; company believes sufficient for 12+ months.","Phase 3 STRIVE-ON trial data presented; GTx-104 showed 19% reduction in hypotension vs. oral nimodipine.","Raised $4.0M through warrant exercises at $3.003/share; 1.35M shares issued."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-004927","json":"https://secwatch.observer/filing/0001140361-26-004927.json","markdown":"https://secwatch.observer/filing/0001140361-26-004927.md","text":"https://secwatch.observer/filing/0001140361-26-004927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126004927/0001140361-26-004927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126004927/ef20064916_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:59:08.375416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}